Cited 0 times in
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이병완 | - |
dc.date.accessioned | 2024-03-22T07:12:45Z | - |
dc.date.available | 2024-03-22T07:12:45Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198706 | - |
dc.description.abstract | Introduction: Glucagon-like peptide-1 receptor agonists are well-established type 2 diabetes (T2D) treatments. As variations among populations and culture might influence treatment effects, this post hoc analysis evaluates the efficacy and safety of once-weekly (OW) semaglutide in a Korean population. Methods: Korean adults with T2D inadequately controlled on metformin included in a 30-week, phase 3a, international, multicentre trial (NCT03061214) compared OW subcutaneous semaglutide (0.5 mg and 1.0 mg) with once-daily sitagliptin (100 mg). Key endpoints included change in glycated haemoglobin (HbA1c) and body weight; additional endpoints assessed proportions of participants reaching targets of HbA1c < 7.0% and ≤ 6.5%, ≥ 5% weight loss, and a composite endpoint of HbA1c < 7.0% without severe/blood glucose-confirmed symptomatic hypoglycaemia and no weight gain. Results: Korean participants (n = 110) showed a greater reduction in HbA1c and body weight with semaglutide 0.5 mg (–1.6%, –2.7 kg) and 1.0 mg (–1.8%, –4.8 kg) versus sitagliptin (–0.9%, 0.5 kg). HbA1c targets of < 7.0% and ≤ 6.5% were achieved by more participants treated with semaglutide 0.5 mg (80.0% and 60.0%, respectively) and 1.0 mg (87.5% and 67.5%, respectively) versus sitagliptin (54.3% and 25.7%, respectively); ≥ 5% weight loss was observed in 42.9% and 65.0% of participants treated with semaglutide 0.5 mg and 1.0 mg versus 0.0% with sitagliptin. The composite endpoint was achieved by 71.4%, 77.5%, and 31.4% of the population in the semaglutide 0.5 mg, 1.0 mg, and sitagliptin group, respectively. No new safety concerns were observed. Conclusion: This analysis confirms efficacy and safety of OW semaglutide (0.5 and 1.0 mg) in a Korean population with T2D. Clinical Trial Registration Number: NCT03061214. © The Author(s) 2024. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer Healthcare | - |
dc.relation.isPartOf | DIABETES THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.contributor.googleauthor | Young Min Cho | - |
dc.contributor.googleauthor | Sin Gon Kim | - |
dc.contributor.googleauthor | Seung-Hyun Ko | - |
dc.contributor.googleauthor | Soo Lim | - |
dc.contributor.googleauthor | Amine Dahaoui | - |
dc.contributor.googleauthor | Jin Sook Jeong | - |
dc.contributor.googleauthor | Hyo Jin Lim | - |
dc.contributor.googleauthor | Jae Myung Yu | - |
dc.identifier.doi | 10.1007/s13300-023-01515-0 | - |
dc.contributor.localId | A02796 | - |
dc.relation.journalcode | J02908 | - |
dc.identifier.eissn | 1869-6953 | - |
dc.identifier.pmid | 38236431 | - |
dc.subject.keyword | Glucagon-like peptide-1 receptor agonist | - |
dc.subject.keyword | Korean population | - |
dc.subject.keyword | NCT03061214 | - |
dc.subject.keyword | Semaglutide | - |
dc.subject.keyword | Type 2 diabetes | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 547 | - |
dc.citation.endPage | 563 | - |
dc.identifier.bibliographicCitation | DIABETES THERAPY, Vol.15(2) : 547-563, 2024-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.